{"filings":[{"id":15041,"accession_number":"0000950103-26-007060","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-05-11T21:01:28+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CRL shareholders approve 2026 LTIP, re-elect all 12 directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2026 Long-Term Incentive Plan approved with 41.5M for vs 2.6M against; 4.825M shares authorized.","All 12 director nominees elected; Abraham Ceesay received highest withhold (8.3M against).","Advisory say-on-pay passed with 41.4M for vs 2.7M against, 1.7M broker non-votes.","Ratification of PricewaterhouseCoopers as auditor approved with 43.6M for vs 2.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91301,"accession_number":"0001100682-26-000036","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q1 GAAP EPS $(0.30), non-GAAP $2.06; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $995.8M (+1.2% reported, -1.5% organic); GAAP loss $(0.30) vs $0.50 prior year.","Non-GAAP EPS $2.06, down 12% YoY; non-GAAP operating margin 16.3% vs 19.1%.","Completed divestiture of CDMO and Cell Solutions to GI Partners on May 6, 2026; European sites expected in May.","Repurchased $200M of stock in Q1; $800M remaining under $1B authorization.","Reaffirmed FY2026 organic revenue (-1.5% to -0.5%) and non-GAAP EPS $10.80-$11.30; lowered reported revenue outlook ~50bps due to FX."],"consensus_eps_estimate":1.9623,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":995830000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101293,"accession_number":"0001628280-26-011395","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Charles River to divest CDMO/Cell Solutions and European Discovery assets; updates 2026 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Definitive agreement to sell CDMO and Cell Solutions to GI Partners for future performance-based payments; $143M 2025 revenue.","Agreement to sell certain European Discovery Services assets to IQVIA for ~$145M cash plus up to $10M contingent; $144M 2025 revenue.","Updated 2026 guidance: reported revenue growth (5.0)% to (3.5)%; non-GAAP EPS $10.80-$11.30.","Divestitures expected to reduce 2026 reported revenue by >$200M, but add at least 100 bps non-GAAP operating margin and ~$0.10 EPS.","Both transactions expected to close in Q2 2026, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101292,"accession_number":"0001100682-26-000020","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Labs Q4 revenue $994M, GAAP loss $5.62; sees 2026 non-GAAP EPS $10.70-$11.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP loss per share $(5.62) from $994.2M revenue (-0.8% YoY); non-GAAP EPS $2.39 (-10.2%).","FY2025 revenue $4.02B (-0.9%); GAAP loss $(2.91)/share; non-GAAP EPS $10.28 (-0.4% vs $10.32).","DSA organic revenue -3.3% in Q4; CEO cites robust DSA net bookings and cautious optimism for demand recovery.","2026 organic revenue guidance (1.0)% to flat; non-GAAP EPS $10.70-$11.20 implies 4-9% growth.","Recorded $211M intangible and $165M goodwill impairments in Biologics Solutions (Manufacturing segment)."],"consensus_eps_estimate":2.3668,"consensus_eps_actual":-2.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":4015382000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101291,"accession_number":"0000950103-26-002326","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Charles River appoints Glenn Coleman as CFO, effective April 6, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Glenn Coleman, 58, joins from Premier, Inc. with 30+ years of financial leadership.","Base salary $800,000; target bonus 85% of base; annual equity award value $3,000,000 for 2026.","One-time new hire cash award of $1,875,000 and equity award of $3,500,000 (RSUs vesting over 4 years).","Coleman succeeds interim CFO Michael Knell, who continues as CAO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101290,"accession_number":"0001628280-26-001905","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Charles River: Q4 DSA book-to-bill ~1.1x; acquires K.F. (Cambodia) for $510M and PathoQuest for ~$60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 DSA net book-to-bill ~1.1x, driven by improved demand from small/mid biotech and global biopharma in Q4.","2026 organic revenue guidance expects at least flat growth for consolidated and DSA, with revenue growth returning in H2 2026.","Non-GAAP operating margin outlook includes >$100M in incremental cost savings to offset inflation until revenue growth resumes.","Acquiring K.F. (Cambodia) for ~$510M; accretive $0.25 in 2026, $0.60 in 2027; close expected early Q1 2026.","Exercising option to buy remaining 79% of PathoQuest for ~€51.6M (~$60M); close by end Q1 2026, not material to 2026/2027 results."],"consensus_eps_estimate":2.3668,"consensus_eps_actual":-2.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":4015382000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101289,"accession_number":"0001628280-26-001603","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Charles River Labs announces CEO transition: Foster to step down, Girshick to become CEO effective May 5, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James C. Foster to step down as CEO and Chairman; Birgit Girshick (COO) to become CEO effective May 5, 2026.","Board size increases from 11 to 12; Dr. Martin Mackay to become Chair; Girshick nominated to Board.","Girshick's base salary increases to $1,200,000, target incentive 100% of salary; initial equity grant $9M (80% PSU/20% RSU).","Foster receives $3M RSU grant; expected to remain non-executive director post-transition.","Elliott Management provides limited consent for Board size increase under May 2025 cooperation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117653,"accession_number":"0001628280-25-054902","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Charles River Labs reports improving DSA book-to-bill trends, encouraged by momentum since mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSA net book-to-bill has improved each month since Q3 2025 started.","Management cites positive momentum and upward trends from mid-2025 onward.","Seasonality around holidays and early January may affect near-term proposal and booking activity.","Update provided at Evercore 8th Annual Healthcare Conference on December 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117652,"accession_number":"0001628280-25-052484","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SEC concludes investigation into Charles River; no enforcement action recommended","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC Division of Enforcement notified company on Nov 14, 2025, that it will not recommend enforcement action.","Investigation began May 16, 2023, focusing on non-human primate sourcing and related disclosures.","Company's independent investigation also concluded with no material findings.","Resolution removes regulatory uncertainty regarding SEC inquiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117651,"accession_number":"0001100682-25-000041","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q3 revenue $1.00B (-0.5% YoY); GAAP EPS $1.10, non-GAAP $2.43","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Organic revenue declined 1.6%; DSA -3.1%, Manufacturing -5.1%, offset by RMS +6.5%.","GAAP net income $54.4M ($1.10/diluted) vs $68.7M ($1.33) a year ago; non-GAAP net income $120.3M ($2.43) vs $133.7M ($2.59).","GAAP operating margin improved to 13.3% (11.6% Q3 2024) on restructuring cost savings; non-GAAP margin dipped to 19.7% (19.9%).","2025 guidance narrowed: reported revenue growth (1.5%)-(0.5%) and non-GAAP EPS $10.10-$10.30, versus prior $9.90-$10.30.","Management sees early positive signals but remains cautious; expects industry recovery to take time."],"consensus_eps_estimate":2.3619,"consensus_eps_actual":2.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":3021155000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134085,"accession_number":"0000950103-25-011896","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K/A","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Interim CFO Michael Knell gets $500k salary, $10k/month stipend, $500k RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary increased to $500,000 effective September 28, 2025.","Monthly cash payment of $10,000 during interim CFO service starting October 1, 2025.","One-time RSU grant of $500,000 in CRL stock on Nov 6, 2025; vests 50% per year over two years.","Knell appointed interim CFO after Flavia H. Pease resigned; serves as interim principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134087,"accession_number":"0000950103-25-011676","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO Flavia Pease resigns; CAO Michael Knell named interim CFO; FY2025 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Flavia H. Pease resigns as CFO effective September 29, 2025, to pursue another opportunity; no disagreements with company.","Michael G. Knell, Corporate SVP & CAO, appointed interim CFO; leads finance organization until permanent successor named.","Company reaffirms 2025 revenue and non-GAAP EPS guidance provided on August 6, 2025, supported by current Q3 outlook.","Comprehensive search for permanent CFO has been launched."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134086,"accession_number":"0001100682-25-000032","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q2 non-GAAP EPS $3.12 beats; raises 2025 guidance; DOJ closes NHP probe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.032B (+0.6% reported; organic -0.5%); GAAP EPS $1.06, non-GAAP EPS $3.12 up 11.4% YoY.","Non-GAAP operating margin improved to 22.1% from 21.3%; DSA non-GAAP margin slightly up to 27.4%.","Raises FY2025 non-GAAP EPS guidance to $9.90-$10.30 (prior $9.30-$9.80); revenue growth (2.5%)-(0.5%).","DOJ closes grand jury and civil investigations into NHP supply chain; no action taken.","Segment organic growth: RMS +2.3%, DSA -2.4%, Manufacturing +2.9%; cost savings from restructuring."],"consensus_eps_estimate":2.5226,"consensus_eps_actual":1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":2016303000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150837,"accession_number":"0001100682-25-000023","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Charles River Labs extends CEO Foster's term to Feb 2027; appoints four new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO James C. Foster's employment term extended by one year to February 12, 2027; all other terms unchanged.","Board appointed Steven Barg, Mark Enyedy, Abraham Ceesay, and Paul Graves as directors, replacing four departing members.","Shareholders elected seven directors, approved executive compensation (advisory) and ratification of PwC as auditor for FY2024.","PETA shareholder proposal to report on non-human primate imports rejected with 38.1M votes against vs 3.5M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150836,"accession_number":"0001100682-25-000019","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q1 revenue down 2.7% to $984.2M; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.50 vs $1.30 YoY; Non-GAAP EPS $2.34 vs $2.27, up 3.1%.","Revenue decline across all segments: RMS -3.5%, DSA -2.1%, Manufacturing -3.6%.","DSA net bookings reached highest level in two years, signaling demand stabilization.","Raised FY2025 Non-GAAP EPS guidance to $9.30-$9.80 from $9.10-$9.60; organic revenue growth range narrowed.","Repurchased $350M of common stock in Q1; $549.3M remaining on $1B authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":984168000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150835,"accession_number":"0000950103-25-005798","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"CRL enters cooperation with Elliott, adds 4 directors, launches strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four new directors (Steven Barg, Abe Ceesay, Mark Enyedy, Paul Graves) to join board after May 20 annual meeting.","Four incumbent directors (Bertolini, Kochevar, Massaro, Wallman) will not stand for re-election at 2025 meeting.","Board will conduct comprehensive strategic review via new Strategic Planning and Capital Allocation Committee.","Cooperation agreement with Elliott includes standstill, voting commitments, and mutual non-disparagement.","Board size capped at 11 members during cooperation period; Barg and Enyedy appointed as Elliott designees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169772,"accession_number":"0001100682-25-000014","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO Foster buys $1M in CRL stock; COO Girshick buys $250K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO James Foster purchased 6,075 shares at avg $165.01 (~$1M); COO Girshick purchased 1,514 shares at avg $164.63 (~$250K) on Feb 20, 2025.","Both terminated existing Rule 10b5-1 trading plans on Feb 19 to allow purchases without violating Section 16 short-swing profit rules.","Foster's plan allowed up to 129,721 shares; he sold 25,000 shares under it in Aug 2024. Girshick's plan allowed up to 22,362 shares; no sales occurred.","Executives cited confidence in strategic direction and long-term growth prospects as reason for open-market purchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169771,"accession_number":"0001100682-25-000009","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Labs Q4 GAAP loss $(4.22) on $215M goodwill impairment; guides FY2025 revenue down 5.5-3.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.00B (-1.1% YoY); non-GAAP EPS $2.66 (+8.1%); GAAP loss $(4.22) from $215M Biologics Solutions goodwill impairment.","Full-year 2024 revenue $4.05B (-1.9%); non-GAAP EPS $10.32 (-3.3%); GAAP EPS $0.20 (-97.8%).","DSA segment revenue down 3.6% organically; Manufacturing organic +2.1%; RMS organic -0.4% despite Noveprim acquisition.","2025 guidance: organic revenue decline 5.5% to 3.5%; non-GAAP EPS $9.10-$9.60; plans $350M stock repurchase.","CEO cites ongoing biopharma client restructuring; expects stable-to-slightly improved biotech demand in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":4049989000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169770,"accession_number":"0001100682-25-000003","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Charles River Labs provides preliminary 2025 outlook: revenue decline, CDMO client losses, potential impairment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects 2025 revenue to decline organically in similar range as estimated 2024; DSA demand consistent with H2 2024.","CDMO revenue headwind: a cell therapy client terminated commercial agreement; lower revenue from another cell therapy client; ~1% consolidated revenue growth drag.","Site consolidation actions (~0.5%) and FX (>1%) also expected to reduce reported revenue in 2025.","Non-GAAP operating margin expected modestly below estimated 2024 level; cost savings cannot fully offset lower revenue.","Assessing recoverability of goodwill and long-lived assets for potential impairment due to CDMO business challenges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186822,"accession_number":"0000950103-24-017767","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Charles River amends credit agreement, cuts revolver to $2B, extends to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving commitments reduced from $3B to $2B; maturity extended to December 13, 2029.","Subsidiary borrower Charles River Laboratories, Inc. added; obligations guaranteed by CRL and secured by assets.","Interest rates based on SOFR/EURIBOR/Base rate plus margin tied to leverage ratio (Level I-III).","Negative covenants limit additional indebtedness, liens, investments, mergers, and asset sales.","Covenants include interest coverage and leverage ratio tests; customary events of default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186821,"accession_number":"0001100682-24-000033","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q3 revenue $1.01B (-1.6% YoY); non-GAAP EPS $2.59 beats prior outlook; narrows FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.01B, down 1.6% YoY (organic -2.7%); GAAP EPS $1.33, non-GAAP EPS $2.59.","DSA segment organic revenue fell 7.4%; Manufacturing organic revenue grew 11.8%.","Board approved $1B stock repurchase; $100.7M spent in Q3, $899.3M remaining.","FY 2024 guidance narrowed: reported revenue (3%)-(2%); non-GAAP EPS raised to $10.10-$10.30.","CEO cites stable demand indicators and biotech funding improvement; restructuring actions continue."],"consensus_eps_estimate":null,"consensus_eps_actual":4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":3047440000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203360,"accession_number":"0001100682-24-000025","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q2 revenue falls 3.2% to $1.03B; slashes FY24 guidance on weak demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.74 (-7.9% YoY); Non-GAAP EPS $2.80 (+4.1%), Non-GAAP net income $144.9M (+4.8%).","DSA organic revenue -5.0%, RMS organic -3.9%; Manufacturing organic +3.7%.","Board authorized new $1.0B share repurchase plan, replacing prior $1.3B authorization.","FY24 guided GAAP EPS $5.65-$5.95 (prior $7.60-$8.10); Non-GAAP EPS $9.90-$10.20 (prior $10.90-$11.40).","Restructuring expected to yield >$150M annual savings; ~$100M realized in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":3.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2037677000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219739,"accession_number":"0001100682-24-000020","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Charles River Labs annual meeting: all director nominees elected, say-on-pay approved, PETA proposal rejected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eleven directors elected; Martin W. Mackay received lowest support with 39.8M for, 6.4M against.","Advisory say-on-pay passed with 43.8M for, 2.3M against.","Ratification of PwC as auditor for fiscal 2024 approved with 45.6M for, 2.6M against.","PETA shareholder proposal on non-human primate import report defeated: 11.4M for, 34.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219738,"accession_number":"0001100682-24-000014","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRL Q1 2024 earnings press release issued; no specific figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for Q1 2024 (ended March 30, 2024) issued on May 9, 2024.","The 8-K body contains no financial data; details are only in Exhibit 99.1.","Investors should review the attached press release for actual results."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1011560000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239521,"accession_number":"0001157523-24-000238","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q4 2023 revenue down 7.9% to $1.01B; non-GAAP EPS $2.46; 2024 guidance organic growth 0-3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $3.62 vs $3.65 YoY; non-GAAP EPS $2.46 vs $2.98, down 17.4%.","Full-year 2023 revenue $4.13B (+3.9%); GAAP EPS $9.22; non-GAAP EPS $10.67.","2024 guidance: organic revenue growth 0%-3%; GAAP EPS $7.90-$8.40; non-GAAP EPS $10.90-$11.40.","Noveprim acquisition completed Nov 2023 (additional 41% stake for $144.6M, now 90% controlling interest).","DSA segment revenue fell 9.5% in Q4; Manufacturing organic growth +2.3% but revenue down 9.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":9.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":4129409000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239520,"accession_number":"0001100682-24-000004","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Charles River Labs appoints Reshema Kemps-Polanco to board; board expands to 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 11 to 12; Kemps-Polanco appointed effective Jan 22, 2024.","She will serve on Compensation Committee and Strategic Planning and Capital Allocation Committee.","Received initial pro-rata equity award valued at $255,500 in RSUs and stock options.","Kemps-Polanco is EVP and Chief Commercial Officer of Novartis US with 25 years pharma experience.","No material transactions or arrangements with Kemps-Polanco requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239519,"accession_number":"0001100682-24-000002","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Charles River Labs CCO William Barbo to retire; Kristen Eisenhauer named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William D. Barbo, Corporate EVP and CCO, to retire at end of 2024 after 42-year career.","Barbo will remain as EVP and strategic advisor until retirement to ensure transition.","Kristen Eisenhauer named SVP and Chief Commercial Officer; 20-year company veteran.","Eisenhauer most recently served as Corporate SVP, Safety Assessment Customer Excellence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257046,"accession_number":"0001100682-23-000025","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO James Foster buys $1M of CRL stock, terminates sell plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO James C. Foster purchased 5,620 shares at average price $178.05 on Nov 14, 2023.","Total purchase price approximately $1.0 million in open market transactions.","Terminated Rule 10b5-1 trading plan dated Feb 24, 2023 that allowed sale of up to 112,341 shares.","Foster cited confidence in strategic direction and long-term growth prospects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257045,"accession_number":"0001157523-23-001678","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q3 results beat; narrows and raises non-GAAP EPS guidance for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.03B (+3.8% YoY); GAAP EPS $1.69 (-10.1%), non-GAAP EPS $2.72 (+3.4%).","Organic revenue growth 4.1%, driven by DSA (+5.3% organic) and RMS (+3.2% organic).","DSA segment GAAP operating margin down to 22.1% from 22.9%; non-GAAP up to 27.2% from 26.2%.","RMS GAAP op margin 15.2% vs 19.9% prior; Manufacturing op margin down on GAAP and non-GAAP basis.","FY2023 guidance: organic rev growth 5.5%-6.5% (narrowed from 5.5%-7.5%); non-GAAP EPS $10.50-$10.70 (prior $10.30-$10.90)."],"consensus_eps_estimate":null,"consensus_eps_actual":5.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":3115933000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274378,"accession_number":"0001157523-23-001294","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q2 revenue up 8.9% to $1.06B; GAAP EPS $1.89, non-GAAP $2.69; guidance narrowed upward","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.06B (+8.9% YoY, organic +11.2%); DSA segment revenue $663.5M (+12.1%) drove growth.","GAAP net income $97.0M (−11.3%), diluted EPS $1.89; non-GAAP EPS $2.69 (−2.9%).","RMS segment revenue $209.9M (+12.6%, organic +13.9%) driven by China model shipments; Manufacturing segment revenue $186.5M (−4.2%).","FY 2023 guidance narrowed: organic revenue growth 5.5%–7.5% (prior 5.0%–7.5%); non-GAAP EPS $10.30–$10.90 (prior $9.90–$10.90).","CEO cites cautious biopharma spending but confidence in differentiated scientific breadth and DSA backlog."],"consensus_eps_estimate":null,"consensus_eps_actual":3.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":2089310000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291631,"accession_number":"0001100682-23-000012","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Charles River Labs annual meeting: directors elected, say-on-pay approved, PETA proposal defeated","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; Martin W. Mackay received 28.5M for vs 17.5M against (significant opposition).","Advisory say-on-pay approved with 40.3M for vs 5.7M against.","Shareholders voted for one-year frequency of say-on-pay votes (45.5M for one year).","Ratification of PwC as auditor approved (45.5M for).","PETA shareholder proposal to report on non-human primate imports defeated (29.4M against vs 16.4M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291630,"accession_number":"0001157523-23-000819","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q1 revenue $1.03B, +12.6% YoY; raises organic growth guidance to 5.0-7.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.01 (+11% YoY); non-GAAP EPS $2.78 (+1.1% YoY); net income $103.1M.","DSA segment revenue $662.4M (+23.6% organic); non-GAAP operating margin 29.0%.","Manufacturing segment revenue $167.3M (-1.8% organic); non-GAAP operating margin 13.7%.","2023 guidance narrowed: organic revenue growth 5.0-7.5% (prior 4.5-7.5%); non-GAAP EPS $9.90-$10.90.","Management cites strong DSA demand but warns Cambodian NHP supply constraints will affect H2."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1029373000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312406,"accession_number":"0001157523-23-000326","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q4 revenue $1.10B (+21.5% YoY); DOJ subpoena on NHP supply; 2023 guidance below expectations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $3.65, non-GAAP EPS $2.98; full-year GAAP EPS $9.48, non-GAAP EPS $11.12.","Q4 organic revenue growth 18.8% led by DSA segment (+26.5% organic).","Received DOJ subpoena on Cambodian NHP supply chain; voluntarily suspended shipments from Cambodia.","2023 guidance: reported revenue growth 1.5%-4.5%, organic 4.5%-7.5%; GAAP EPS $7.40-$8.60, non-GAAP $9.70-$10.90.","NHP supply constraints expected to reduce 2023 revenue growth by 200-400 bps; higher tax and interest to pressure EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":9.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":3976060000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330950,"accession_number":"0001100682-22-000037","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Charles River Labs appoints Dr. Craig B. Thompson to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 10 to 11; Dr. Thompson appointed effective Dec. 5, 2022.","Appointed to Science & Technology Committee and Strategic Planning & Capital Allocation Committee.","Initial pro-rata equity award valued at $255,500 (50% RSUs, 50% stock options).","Thompson is former CEO of Memorial Sloan Kettering (2010-2022) and current Regeneron board member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330949,"accession_number":"0001100682-22-000035","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-11-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Charles River addresses NHP supply disruption risk following DOJ charges against Cambodian supplier","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company not named in DOJ proceedings; no direct contracts with indicted Cambodian supplier.","Obtains NHPs from multiple global sources including Cambodia, but expects Cambodia-sourced supply to be difficult for some time.","Actively working to mitigate impact by procuring NHPs from alternative supply arrangements and other global sources.","Presentation at Evercore ISI conference on Nov 30, 2022 to discuss NHP supply chain and DOJ impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330948,"accession_number":"0001157523-22-001470","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q3 revenue $989.2M (+10.4% YoY); raises guidance, plans Avian Vaccine sale for ~$170M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $989.2M (+10.4% YoY, organic +15.3%); GAAP EPS $1.88 (-6.5%), non-GAAP EPS $2.63 (-2.6%).","DSA segment revenue $619.5M (+16.5%) drove results; Manufacturing declined -1.7% to $189.6M.","Narrows 2022 guidance: reported revenue growth 10-11%, non-GAAP EPS $10.80-10.95 (prior $10.70-10.95).","Announced divestiture of Avian Vaccine business for ~$170M cash plus up to $30M contingent; close expected by year-end.","Divestiture to reduce 2023 revenue by ~$80M and non-GAAP EPS by ~$0.35 before redeployment of proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":5.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":2876217000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348499,"accession_number":"0001157523-22-000999","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q2 revenue $973.1M (+6.4% YoY); non-GAAP EPS $2.77 (+6.1%); cuts FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.13 vs $1.72 Q2 2021; non-GAAP EPS $2.77 vs $2.61.","Revenue $973.1M, organic growth 9.5% led by DSA and RMS segments.","FY22 guidance cut: organic rev growth 10-12% (prev 12.5-14.5%), non-GAAP EPS $10.70-$10.95 (prev $11.50-$11.75).","DSA segment revenue $591.9M (+12.9% organic); operating margin improved to 25.3% non-GAAP.","Manufacturing segment revenue $194.8M (-1.5%); CDMO weakness offset by Biologics Testing growth."],"consensus_eps_estimate":null,"consensus_eps_actual":3.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":1887060000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365202,"accession_number":"0001100682-22-000023","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Charles River lowers Q2 2022 revenue and EPS outlook, cites FX and CDMO headwinds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 reported revenue growth guidance cut from low-double-digit to high-single-digit YoY; non-GAAP EPS growth cut from mid- to high-single-digit to low- to mid-single-digit.","Guidance reduction driven by unfavorable FX impact and manufacturing (CDMO) revenue growth below Q1 2022 level.","DSA and RMS organic growth rates expected to accelerate from Q1; DSA trends remain in line with full-year expectations.","Full-year 2022 organic revenue growth and non-GAAP EPS guidance maintained within prior ranges provided in May."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365201,"accession_number":"0001100682-22-000020","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CRL shareholders elect all 10 director nominees, approve say-on-pay and auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; James C. Foster received 42,534,751 votes for and 2,405,964 against.","Advisory say-on-pay resolution passed with 39,792,720 votes for and 5,179,352 against.","Ratification of PwC as independent auditor approved with 44,673,788 votes for and 2,366,772 against.","Broker non-votes: 2,058,945 on director elections and say-on-pay; zero on auditor ratification.","Annual meeting held May 10, 2022; results filed May 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365200,"accession_number":"0001157523-22-000551","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q1 revenue $913.9M (+10.8%), GAAP EPS $1.81, non-GAAP EPS $2.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $913.9M (+10.8% YoY); organic growth 9.4%; GAAP net income $93.0M (+51.2%); non-GAAP net income $141.1M (+9.3%).","Segment revenue: RMS $176.5M (flat), DSA $544.3M (+8.6%), Manufacturing $193.1M (+31.8% driven by CDMO acquisitions).","2022 guidance updated: reported revenue growth raised to 13.5%-15.5% (from 13-15%); organic growth unchanged 12.5%-14.5%; non-GAAP EPS reaffirmed $11.50-$11.75.","DSA segment reported record booking activity and strong backlog growth, with studies booked into 2023.","Foreign currency reduced reported revenue growth by 1.7%; acquisitions contributed 4.7%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":913929000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384791,"accession_number":"0001100682-22-000010","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Charles River Labs appoints Flavia Pease as CFO; David Smith retires to Senior Advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Flavia Pease named Corporate EVP and CFO effective after Q1 2022 10-Q filing (~early May 2022).","Pease joins from J&J, where she was VP and Group CFO of global Medical Devices ($27B revenue).","Outgoing CFO David Smith will become Senior Financial Advisor until February 2023.","Pease receives $600K base salary, 70% target bonus, $2M equity award, plus $1.7M new-hire equity.","One-time signing bonus of $800,000, with $200K within 30 days and $600K after 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384790,"accession_number":"0001157523-22-000208","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q4 rev $905.1M (+14.4%); reaffirms 2022 guidance with non-GAAP EPS $11.50-$11.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $2.67 vs $2.81 prior year (-5%); non-GAAP EPS $2.49 vs $2.39 (+4.2%).","Full-year 2021 revenue $3.54B (+21.1%); organic growth 15.1%; non-GAAP EPS $10.32 (+26.9%).","RMS segment organic growth 13.3%; DSA organic growth 6.7%; Manufacturing organic growth 21.2%.","2022 guidance: organic revenue growth 12.5-14.5%; non-GAAP EPS $11.50-$11.75; free cash flow ~$450M.","GAAP net income Q4 $137.6M vs $143.2M; full-year $391M vs $364.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":7.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":3540160000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384789,"accession_number":"0001100682-22-000002","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Charles River Labs CFO David Smith to retire; provides preliminary 2022 guidance","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["CFO David R. Smith will retire; he will remain until a successor is named, expected by end of 2022.","At J.P. Morgan Healthcare Conference, management presented preliminary 2022 outlook for revenue growth, organic revenue growth, non-GAAP operating margin, non-GAAP EPS, free cash flow, and capex.","Specific numerical guidance was not included in the filing; slide deck is available on the company's IR website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402683,"accession_number":"0001100682-21-000028","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2021-12-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRL grants $5M long-term equity award to EVP LaPlume with 5-year cliff vesting and rTSR PSUs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joseph W. LaPlume receives $5M total fair value: 50% RSUs (6,771 units) cliff vesting Dec 25, 2026.","50% in PSUs (5,096 target) based on 5-year relative TSR vs S&P Healthcare 500, payout 0%-200%.","Grant effective Dec 25, 2021; recognizes LaPlume's contributions and critical role in strategic growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402682,"accession_number":"0001100682-21-000025","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Charles River Laboratories adopts proxy access bylaw amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders owning at least 3% of outstanding stock for 3+ years can nominate directors.","Groups of up to 20 stockholders may aggregate ownership to meet the threshold.","Nominees can constitute up to the greater of 2 directors or 20% of the board.","Amendments effective December 13, 2021; includes conforming and routine updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402681,"accession_number":"0000950103-21-017730","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Charles River Laboratories promotes Birgit Girshick to COO, adds Research Models & Services oversight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Birgit Girshick promoted to Executive VP and COO, effective November 11, 2021.","She adds Research Models and Services to her existing responsibilities for Discovery, Safety Assessment, Biologics Solutions, and Cell & Gene Therapy CDMO.","Girshick has been with Charles River since 1989, leading strategic initiatives and integrating acquisitions like Cognate BioServices and Vigene Biosciences.","James C. Foster remains Chairman, President and CEO; his employment agreement was extended to February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402680,"accession_number":"0000950103-21-017524","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Charles River previews 2022: low-double-digit organic revenue growth, margin expansion, 9% capex","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects low-double-digit organic revenue growth in 2022 driven by sustained robust demand.","Non-GAAP operating margin improvement targeted towards ~22.5% by 2024.","Staffing levels increased ahead of plan; compensation expected to be headwind in 2022.","Capital expenditure guided at ~9% of total revenue in 2022, mainly for Safety Assessment capacity.","Outlook presented at Credit Suisse 30th Annual Healthcare Conference on Nov 9, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402679,"accession_number":"0001157523-21-001314","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q3 revenue $895.9M (+20.5% YoY); non-GAAP EPS $2.70; updates 2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $895.9M, +20.5% YoY; organic growth 13.6% with contributions from all three segments.","GAAP EPS $2.01 (-1.0% YoY) includes $0.15 loss from venture investments; non-GAAP EPS $2.70 (+15.9%).","RMS segment revenue $171.3M (+12.7% YoY); DSA $531.8M (+15.3%); Manufacturing $192.9M (+48.1%).","2021 guidance: reported revenue growth 19.5%-20.5% (from 20.5%-22.5%); GAAP EPS raised to $7.05-$7.15; non-GAAP EPS $10.20-$10.30.","Completed divestitures of RMS Japan and CDMO Sweden on Oct 12; reduces Q4 revenue ~$20M and non-GAAP EPS <$0.10."],"consensus_eps_estimate":null,"consensus_eps_actual":4.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":2635110000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421593,"accession_number":"0001157523-21-000990","cik":1100682,"company_name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","ticker":"CRL","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Charles River Q2 revenue $914.6M (+34% YoY); raises 2021 guidance above prior estimates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $914.6M, +34% YoY (organic +24.1%); GAAP EPS $1.72, non-GAAP EPS $2.61.","Non-GAAP EPS of $2.61 beat prior year $1.58; net income $88.4M GAAP, $133.8M non-GAAP.","All three segments drove organic growth: RMS +44.5%, DSA +18.1%, Manufacturing +26.6%.","2021 guidance raised: revenue growth 20.5-22.5% (was 19-21%), non-GAAP EPS $10.10-$10.35 (was $9.75-$10.00), FCF ~$500M.","CEO cites robust client demand and strengthened portfolio; company adding staff and capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":2.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":1739173000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8597217976.2319,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}